• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

换用恩曲他滨/替诺福韦艾拉酚胺进行人类免疫缺陷病毒暴露前预防后的急性体重增加

Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis.

作者信息

Selvaraj Shailendra V, Bares Sara H, Havens Joshua P

机构信息

Department of Pharmacy Practice, University of Nebraska Medical Center, Omaha, Nebraska, USA.

Department of Internal Medicine, Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.

出版信息

Open Forum Infect Dis. 2020 Sep 24;7(10):ofaa454. doi: 10.1093/ofid/ofaa454. eCollection 2020 Oct.

DOI:10.1093/ofid/ofaa454
PMID:33134420
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7588108/
Abstract

We report a case of acute weight gain after switching from emtricitabine/tenofovir disoproxil to emtricitabine/tenofovir alafenamide for human immunodeficiency virus pre-exposure prophylaxis.

摘要

我们报告了一例在将用于人类免疫缺陷病毒暴露前预防的恩曲他滨/替诺福韦酯换成恩曲他滨/替诺福韦艾拉酚胺后出现急性体重增加的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5099/7588108/a5a15ca09e34/ofaa454_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5099/7588108/a5a15ca09e34/ofaa454_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5099/7588108/a5a15ca09e34/ofaa454_fig1.jpg

相似文献

1
Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis.换用恩曲他滨/替诺福韦艾拉酚胺进行人类免疫缺陷病毒暴露前预防后的急性体重增加
Open Forum Infect Dis. 2020 Sep 24;7(10):ofaa454. doi: 10.1093/ofid/ofaa454. eCollection 2020 Oct.
2
Emtricitabine + tenofovir alafenamide for the treatment of HIV.
Expert Opin Pharmacother. 2017 Mar;18(4):427-432. doi: 10.1080/14656566.2017.1288720. Epub 2017 Feb 8.
3
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.替诺福韦艾拉酚胺/恩曲他滨与阿巴卡韦/拉米夫定用于治疗病毒学抑制的 HIV-1 感染成人：一项随机、双盲、活性对照、非劣效性 3 期试验。
Lancet HIV. 2018 Apr;5(4):e162-e171. doi: 10.1016/S2352-3018(18)30010-9. Epub 2018 Feb 20.
4
Case Report: Reversal of Integrase Inhibitor- and Tenofovir Alafenamide-Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF.病例报告：换回依非韦伦/恩曲他滨/替诺福韦酯后，整合酶抑制剂和替诺福韦艾拉酚胺相关体重增加的逆转
Open Forum Infect Dis. 2021 Aug 2;8(8):ofab403. doi: 10.1093/ofid/ofab403. eCollection 2021 Aug.
5
Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.从利匹韦林/替诺福韦二吡呋酯富马酸/恩曲他滨转换为利匹韦林/替诺福韦艾拉酚胺/恩曲他滨后血脂谱的变化：基线高胆固醇血症患者与无基线高胆固醇血症患者的不同影响。
PLoS One. 2019 Oct 11;14(10):e0223181. doi: 10.1371/journal.pone.0223181. eCollection 2019.
6
Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial.单片复方埃替拉韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺用于病毒学抑制的HIV感染儿童的安全性、疗效及药代动力学：一项单臂、开放标签试验
Lancet Child Adolesc Health. 2017 Sep;1(1):27-34. doi: 10.1016/S2352-4642(17)30009-3. Epub 2017 Jun 29.
7
Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient.在一名感染HIV的患者中，由富马酸替诺福韦二吡呋酯导致的范科尼综合征通过换用富马酸替诺福韦艾拉酚胺得以逆转。
Ther Adv Infect Dis. 2018 Jul 10;5(5):91-95. doi: 10.1177/2049936118785497. eCollection 2018 Sep.
8
Drug safety evaluation of oral tenofovir disoproxil fumarate-emtricitabine for pre-exposure prophylaxis for human immunodeficiency virus infection.口服替诺福韦酯-恩曲他滨用于人类免疫缺陷病毒感染暴露前预防的药物安全性评价。
Expert Opin Drug Saf. 2016 Sep;15(9):1287-94. doi: 10.1080/14740338.2016.1211108. Epub 2016 Jul 25.
9
Recovery of Tenofovir-induced Nephrotoxicity following Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Human Immunodeficiency Virus-Positive Patients.在人类免疫缺陷病毒阳性患者中，从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺后，替诺福韦诱导的肾毒性的恢复情况。
Infect Chemother. 2020 Sep;52(3):381-388. doi: 10.3947/ic.2020.52.3.381. Epub 2020 Jul 16.
10
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.对于未感染艾滋病毒的青春期男孩和年轻男性，在用于艾滋病毒暴露前预防时，富马酸替诺福韦二吡呋酯/恩曲他滨导致的骨量下降与无肾功能损害情况下的激素变化有关。
Clin Infect Dis. 2017 Feb 1;64(3):317-325. doi: 10.1093/cid/ciw765. Epub 2016 Nov 15.

引用本文的文献

1
No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain.无替诺福韦艾拉酚胺和/或整合酶抑制剂相关体重增加快速逆转的证据。
AIDS. 2023 Oct 1;37(12):1843-1850. doi: 10.1097/QAD.0000000000003654. Epub 2023 Jul 26.
2
Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?整合酶抑制剂与替诺福韦艾拉酚胺导致的体重过度增加：机制是什么，这重要吗？
Open Forum Infect Dis. 2021 Nov 17;8(12):ofab542. doi: 10.1093/ofid/ofab542. eCollection 2021 Dec.

本文引用的文献

1
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen.从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺会导致基于利匹韦林方案的患者体重增加。
AIDS. 2020 May 1;34(6):877-881. doi: 10.1097/QAD.0000000000002496.
2
Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.抗逆转录病毒治疗起始后体重增加：随机对照临床试验中的危险因素。
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389. doi: 10.1093/cid/ciz999.
3
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
多替拉韦加利伟酯联合两种不同的替诺福韦前药治疗 HIV。
N Engl J Med. 2019 Aug 29;381(9):803-815. doi: 10.1056/NEJMoa1902824. Epub 2019 Jul 24.
4
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.初治人群开始使用多替拉韦为基础的抗逆转录病毒治疗时体重增加较多。
Clin Infect Dis. 2020 Mar 17;70(7):1267-1274. doi: 10.1093/cid/ciz407.
5
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.恩曲他滨替诺福韦复方制剂预防用药的代谢效应。
Clin Infect Dis. 2018 Jul 18;67(3):411-419. doi: 10.1093/cid/ciy083.
6
Attenuating the Biologic Drive for Weight Regain Following Weight Loss: Must What Goes Down Always Go Back Up?减轻体重减轻后体重反弹的生物学驱动力：下降的体重就一定会反弹吗？
Nutrients. 2017 May 6;9(5):468. doi: 10.3390/nu9050468.
7
Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.生命体征：2015 年美国有指征进行暴露前预防以预防艾滋病毒感染的成年人的估计百分比和人数。
MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1291-5. doi: 10.15585/mmwr.mm6446a4.
8
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.恩曲他滨/替诺福韦对HIV阴性者骨矿物质密度影响的随机双盲安慰剂对照试验
Clin Infect Dis. 2015 Aug 15;61(4):572-80. doi: 10.1093/cid/civ324. Epub 2015 Apr 23.
9
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.与恩曲他滨/富马酸替诺福韦二吡呋酯用于HIV暴露前预防相关的肾功能变化。
AIDS. 2014 Mar 27;28(6):851-9. doi: 10.1097/QAD.0000000000000156.
10
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.在曼谷泰国注射吸毒者中预防艾滋病毒感染的抗逆转录病毒预防（曼谷替诺福韦研究）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2013 Jun 15;381(9883):2083-90. doi: 10.1016/S0140-6736(13)61127-7. Epub 2013 Jun 13.